NICE have deemed daclizumab to be cost effective to treat pwMS with more active MS

On the Barts Blog:

PwMS living in England; NICE have deemed daclizumab to be cost effective to treat pwMS with more active MS and in whom alemtuzumab is contraindicated or otherwise unsuitable.

On the MS Society website too:

Who can take it?

NICE have approved the treatment for people who have:

  • ‘Active’ relapsing MS that’s been treated with another disease modifying treatment.
  • ‘Rapidly evolving severe’ MS (defined by at least 2 relapses in the previous year and an MRI scan showing new lesions)

It will only be available to people who are unable or unwilling to take alemtuzumab.